Scripps research scientists 'watch' as individual alpha-synuclein proteins change shape

March 17, 2009

Dance by protein linked to Parkinson's and Alzheimer's diseases reveals unprecedented twists and turns

In an Early Edition publication of The Proceedings of the National Academy of Sciences (PNAS) this week, the researchers demonstrate the "alpha-synuclein dance" - the switching back and forth of the protein between a bent helix and an extended helix as the surface that it is binding to changes.

Such shape shifting has rarely been so directly observed in proteins like alpha-synuclein, which are known to be unfolded in isolation, says the study's senior investigator Ashok Deniz, an associate professor at The Scripps Research Institute.

"We are intrigued to see such complex behavior," he says. "It is interesting that with just a single binding partner, the protein can undergo so many dramatic shape transitions, and that the whole process is reversible."

In the past, scientists believed that proteins, as directed by their genes, fold themselves into defined three-dimensional structures that dictate their function. But more recently, a class of proteins known as "intrinsically disordered proteins" have been identified, which are functional, despite the fact that they are often unfolded.

Alpha-synuclein is such a protein. Mutations in the gene that produces alpha-synuclein have been linked to early-onset Parkinson's disease, and in sporadic, common Parkinson's disease, the protein can accumulate into so-called Lewy bodies inside nerve cells. The protein is also found in the amyloid plaques in Alzheimer's disease, and in other forms of neurological disease.

To learn more about alpha-synuclein, the Scripps Research team decided to study the shape of single proteins. To do this, they used a technique they helped develop, which is known as single-molecule fluorescence resonance energy transfer (FRET), to look at how the protein folds when it binds to different molecules. This technique, which Deniz calls a "molecular ruler," measures light emitted from fluorescent dyes that are attached to amino acids in the protein. The measured light provides information about molecular distances, hence revealing the protein's shape. By observing shapes of individual proteins rather than averaging data over a large number of them, the team was able to better map and resolve shape complexity in the system.

To coax the protein to change shapes, the researchers increased the concentration of a soapy solution that mimics the lipids found in different nerve cell membranes in the brain. Alpha-synuclein is known to bind to membranes on nerve cells, and lipids are a large component of those membranes.

At a low concentration, the "lipid" molecules remained separate but at higher concentration, small and then larger blobs of molecules form. The shape of the alpha-synuclein kept pace - the extended helix could latch onto lipid-mimics as monomers or in a large cylinder-shaped blob, whereas the bent helix wrapped itself around smaller lipid-mimic balls or could create formations with lipid-mimic monomers.

"Others have found the protein to be in a bent helix or in an extended helix, but what we are showing here directly is that the shape can actively change," Deniz says. "It starts off in an unfolded state, and as we increase the concentration of the lipid mimics, the protein reacts to what is in effect a different binding partner, even though it is the same small molecule at different concentrations. It switches back and forth into different states.

"This is perhaps the most complex protein folding-binding system that has been studied to date using single-molecule FRET," he says.

This ability of alpha-synuclein to be switched into alternative shapes could play a significant role in regulating formation of disease-related aggregates, as well as enabling its function. Hence, one next step for the research team is to figure out which form of alpha-synuclein may accelerate formation of the types of protein aggregates found in Alzheimer's disease plaque and in Parkinson's disease Lewy bodies. Using single-molecule methods to directly construct binding-folding maps (as in the current work) will be a critical component of this future effort, and also should be widely applicable to other intrinsically disordered or amyloid-forming proteins.

Scripps Research Institute

---

---

	Alpha-Synuclein: Webster's Timeline History, 1995 - 2007 by Icon Group International (Author) Webster's bibliographic and event-based timelines are comprehensive in scope, covering virtually all topics, geographic locations and people. They do so from a linguistic point of view, and in the case of this book, the focus is on "Alpha-Synuclein," including when used in literature (e.g. all authors that might have Alpha-Synuclein in their name). As such, this book represents the largest compilation of timeline events associated with Alpha-Synuclein when it is used in proper noun form. Webster's timelines cover bibliographic citations, patented inventions, as well as non-conventional and alternative meanings which capture ambiguities in usage. These furthermore cover all parts of speech (possessive, institutional usage, geographic usage) and contexts, including pop culture, the arts,...
	Suppressive effect of anti-inflammatory drugs, fisetin and ibuprofen on MPTP induced alpha-synuclein expression and PC12 neuronal cell death. by Hirenkumar V Panchal (Author) Recently, it has been shown that alpha-synuclein oligomers and neuroinflammation can play an important role in the development of Parkinson's disease, Alzheimer's disease, and dementia. In Parkinson's disease, alpha-synuclein oligomers accumulate in the synapses, leading to the death of neurons due to neuroinflammation, which inhibits the production of Dopamine. MPTP produces neurodegeneration in the dopaminergic nigrostriatal system, the structure of the basal ganglia, which is primarily affected in Parkinson's disease. MPTP induces PC12 cell death, and increases the expression of a 57 kDa species of a-synuclein. The main reasons for neuronal loss could be the oxidation or inflammation in neurons. This study, investigated the potential cytoprotective effect of two anti-inflammatory...
	Regulation of the synaptic vesicle cycle and mitochondrial morphology by alpha-synuclein. by Venu Maadhav Nemani (Author) Neurodegenerative diseases are characterized by the accumulation and aggregation of particular proteins. In most cases, very little is known about the physiological function of these proteins; further, the manner in which their normal functions may contribute to the initiation of disease has not been well studied. The protein alpha-synuclein has been implicated in both sporadic and familial forms of Parkinson's disease. Three point mutations in alpha-synuclein cause dominantly inherited forms of the disease, implying a causative role in the disorder. Although it localizes to nerve terminals, its role in neurotransmitter release remains poorly understood. Recently, it has been shown that modest increases in alpha-synuclein protein expression are sufficient to cause Parkinson's disease,...
	Solid-state nuclear magnetic resonance spectroscopy of alpha-synuclein fibrils. by Kathryn D Kloepper (Author) Recent solid-state NMR (SSNMR) studies on protein systems such as beta-amyloid and the prion HET-s demonstrate the applicability of these techniques towards solving 3D structures of amyloid fibrils. Alpha-synuclein is a 140-residue protein that has been implicated in Parkinson's disease. Fibrils of alpha-synuclein are the primary fibrillar component of Lewy bodies, which are the pathological hallmark of the disease; however, the role that synuclein plays in the disease is uncertain, due largely to a lack of atomic-resolution structural information. Here we present structural studies of fibrils of alpha-synuclein. In this work, we first optimized an expression and purification scheme for the production of uniformly 13C and 15N labeled synuclein. We then developed a protocol for the...
	Tyrosine and the oxidative aggregation of alpha-synuclein. by Rebecca A S Ruf (Author) Oxidative stress and aggregation of the protein alpha-synuclein are thought to be key factors in Parkinson's disease. Previous work shows that cytochrome c plus H2O2 causes tyrosine-dependent in vitro peroxidative aggregation of proteins, including alpha-synuclein. Herein, I detail a method for monitoring alpha-synuclein and cytochrome c in a variety of experiments. Using this system, I examine the role of each of alpha-synuclein's four tyrosine residues and how the protein's conformation affects covalent oxidative aggregation. When alpha-synuclein adopts a collapsed conformation, tyrosine 39 is essential for wild-type-like covalent aggregation. This lone N-terminal tyrosine, however, is not required for wild type-like covalent aggregation in the presence of a denaturant or when...
	Untersuchung der Neuropathologie konditionalerMausmodelle des Morbus Parkinson: Reversibilitäts-Analyse des Einflusses von alpha-Synuclein in vivo by Nuber Silke (Author)
	Fatal Attractions: Protein Aggregates in Neurodegenerative Disorders (Research and Perspectives in Alzheimer's Disease) by V.M.-Y. Lee (Editor), J.Q. Trojanowski (Editor), L. Buee (Editor), Y. Christen (Editor) In this volume are contributions based on a meeting arranged by the WHO and the Fondation IPSEN. The scientists focus on neurodegenerative disorders like Alzheimer's Disease, Chromosome 17-Linked Dementia, Parkinson's Disease and disorders with tauopathies.
	NEURODEGENERATIVE DISORDERS ASSOCIATED WITH ALPHA-SYNUCLEIN by EDUARDO TOLOSA SARRO (Author)
	The Parkinson's Disease Treatment Book: Partnering with Your Doctor to Get the Most from Your Medications by J. Eric Ahlskog M.D. Ph.D. (Author) Nearly one million Americans, including Michael J. Fox and Muhammad Ali, suffer from Parkinson's Disease. Now, a leader in the fight against Parkinson's, Dr. J. Eric Ahlskog of the Mayo Clinic, has written the definitive guide for patients and their families. Dr. Ahlskog offers a crystal-clear, nuts-and-bolts approach to the treatment of PD, distilled from over twenty years of experience as a clinician and researcher. His goal is to educate the patient so that they can better team with their doctor to do battle with the disease, streamlining the decision-making process and enhancing their treatment. To do this, Dr. Ahlskog offers a gold mine of information: How do I know if I have PD? What kinds of tests can I take? What medications slow the progress of the disease? What if...
	Natural Therapies for Parkinson's Disease by Dr. Laurie Mischley (Author) Conventional management of Parkinson's disease (PD) is limited. The pharmaceutical and surgical options that are available have significant side effects and only correct symptoms for a limited period of time. Even with the best conventional treatment, the disease progresses and becomes severely disabling. No existing conventional therapies that the progress of the disease; available medicines only treat symptoms temporarily. Conventional medicine views the course of the disease as "progressive" and "irreversible." Many patients, who are only partially satisfied with conventional medicine, seek alternative and complementary options in an attempt to slow, stop, or reverse the disease process. This book has several functions: - It is a science-based reference manual. - It is inspiring...